3/16
10:58 am
kymr
Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/14
05:36 pm
kymr
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]
Low
Report
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]
3/12
01:21 pm
kymr
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
07:08 am
kymr
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
3/10
07:00 am
kymr
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
3/9
10:47 pm
kymr
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]
Low
Report
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]
3/7
02:59 am
kymr
Low
Report
3/3
02:22 pm
kymr
Kymera Therapeutics (KYMR) had its price target raised by UBS Group AG from $90.00 to $128.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by UBS Group AG from $90.00 to $128.00. They now have a "buy" rating on the stock.
3/2
01:53 pm
kymr
Kymera Therapeutics (KYMR) had its price target raised by Citigroup Inc. from $110.00 to $120.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by Citigroup Inc. from $110.00 to $120.00. They now have a "buy" rating on the stock.
3/2
09:27 am
kymr
Kymera Therapeutics (KYMR) had its price target raised by Stephens from $95.00 to $100.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by Stephens from $95.00 to $100.00. They now have an "overweight" rating on the stock.
2/28
03:42 pm
kymr
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans [Yahoo! Finance]
Low
Report
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans [Yahoo! Finance]
2/28
01:40 pm
kymr
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]
Low
Report
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]
2/27
09:16 am
kymr
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler [Yahoo! Finance]
Medium
Report
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler [Yahoo! Finance]
2/26
05:33 pm
kymr
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
05:03 pm
kymr
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
Medium
Report
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
2/26
02:11 pm
kymr
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Medium
Report
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
2/26
01:58 pm
kymr
Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.
Medium
Report
Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.
2/26
11:52 am
kymr
Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.
Medium
Report
Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.
2/26
07:32 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
High
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
2/26
07:00 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Medium
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
2/24
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
2/19
07:34 am
kymr
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
2/19
07:00 am
kymr
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Low
Report
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2/4
07:18 am
kymr
Kymera Therapeutics to Participate in Upcoming February Investor Conferences [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Participate in Upcoming February Investor Conferences [Yahoo! Finance]
2/4
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming February Investor Conferences